Taking into account that some available DMTs stimulate the production of anti-inflammatory interleukins, such as IL-4 and IL-10 [23], the EV protein content from immune system cells in patients with MS could have a role as a marker of whether DMTs are properly activating anti-inflammatory pathways, and it likely contributes to reducing CNS injury. This evidence concerns the gene IL4 and myeloid sarcoma.